SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Guo, J. Articles by Arlinghaus, R. Search for Related Content PubMed PubMed Citation Articles by Guo, J. Articles by Arlinghaus, R. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy JQ Guo, JY Lian, YM Xian, MS Lee, AB Deisseroth, SA Stass, RE Champlin, M Talpaz, JY Wang and RB Arlinghaus Department of Biology, University of California at San Diego, La Jolla. Chronic myelogenous leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome (Ph1) in more than 95% of these patients. The Ph1 and the resulting BCR-ABL fused genes are markers for this type of leukemia. In CML, the product of the fused BCR- ABL gene is typically a protein of approximately 2,000 amino acids termed P210 BCR-ABL. We have developed an assay for the BCR-ABL protein involving Western blotting of circulating white blood cells (WBC) with an anti-ABL monoclonal antibody that can detect P210 BCR-ABL and P145 ABL in peripheral blood cells from chronic phase Ph1-positive leukemia patients. This assay was used to analyze the BCR-ABL protein content of circulating WBC from CML patients before and after various treatments. In parallel to changes in percentages of Ph1-positive blood cells as determined by cytogenetic analyses of bone marrow samples, BCR-ABL protein expression in blood cells decreased or increased as patients entered remission or underwent relapse. Of interest, six Ph1-negative CML patients were BCR-ABL protein-positive. All except one had a rearrangement in the major breakpoint cluster region and that patient expressed P185 BCR-ABL and not P210. Our results indicate that the BCR- ABL Western blotting assay has clinical applications for both diagnosis and prospective evaluation of Ph1-positive and Ph1-negative CML patients. Volume 83, Issue 12, pp. 3629-3637, 06/15/1994 Copyright © 1994 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: X. Ling, G. Ma, T. Sun, J. Liu, and R. B. Arlinghaus Bcr and Abl Interaction: Oncogenic Activation of c-Abl by Sequestering Bcr Cancer Res., January 15, 2003; 63(2): 298 - 303. [Abstract] [Full Text] [PDF] B. Falini and D. Y. Mason Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry Blood, January 15, 2002; 99(2): 409 - 426. [Abstract] [Full Text] [PDF] Y. Wang, J. Liu, Y. Wu, W. Luo, S.-H. Lin, H. Lin, N. Hawk, T. Sun, J. Q. Guo, Z. Estrov, et al. Expression of a Truncated First Exon BCR Sequence in Chronic Myelogenous Leukemia Cells Blocks Cell Growth and Induces Cell Death Cancer Res., January 1, 2001; 61(1): 138 - 144. [Abstract] [Full Text]

	Copyright © 1994 by American Society of Hematology         Online ISSN: 1528-0020